



## **Enanta Pharmaceuticals to Present at the Wells Fargo Securities 2013 Healthcare Conference**

June 14, 2013

[Download this Press Release](#)

WATERTOWN, Mass.--(BUSINESS WIRE)--Jun. 14, 2013-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present a corporate overview followed by a Q&A session and participate in a Hepatitis C panel discussion on June 18, 2013 at the Wells Fargo Securities 2013 Healthcare Conference in Boston, MA. The panel discussion will take place at 10:00 a.m. ET and the presentation will take place at 11:10 a.m. ET.

The panel discussion and presentation will be webcast live and a replay can be accessed by visiting the Investor homepage section of Enanta's website at [www.enanta.com](http://www.enanta.com). A replay of the webcasts will be available following the presentations and will be archived for approximately 30 days.

### **About Enanta**

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a current focus on developing an intravenous and oral treatment for hospital and community MRSA (methicillin-resistant *Staphylococcus aureus*) infections.

Source: Enanta Pharmaceuticals, Inc.

### **Investor Contact**

Enanta Pharmaceuticals, Inc.

Carol Miceli, 617-607-0710

[cmiceli@enanta.com](mailto:cmiceli@enanta.com)